U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C2H4O2
Molecular Weight 60.052
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Acetic acid

SMILES

CC(O)=O

InChI

InChIKey=QTBSBXVTEAMEQO-UHFFFAOYSA-N
InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)

HIDE SMILES / InChI
Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.

CNS Activity

Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CYANOKIT

Approved Use

Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3)

Launch Date

2006
Curative
VOSOL

Approved Use

For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial.

Launch Date

1960
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4511.6 μM × h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.2 h
5 g single, intravenous
dose: 5 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROXOCOBALAMIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, intramuscular
Dose: 20 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 13 years
Health Status: unhealthy
Age Group: 13 years
Sex: M
Sources:
20 g single, intravenous
Highest studied dose
Dose: 20 g
Route: intravenous
Route: single
Dose: 20 g
Sources:
unhealthy, 26.9 years
Health Status: unhealthy
Age Group: 26.9 years
Sex: M
Sources:
5 g single, intravenous
Overdose
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 3 years
Health Status: unhealthy
Age Group: 3 years
Sex: F
Sources:
5 g single, intravenous
Dose: 5 g
Route: intravenous
Route: single
Dose: 5 g
Sources:
unhealthy, 62 years
Health Status: unhealthy
Age Group: 62 years
Sex: M
Sources:
2000 ug 2 times / day multiple, oral
Dose: 2000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 2000 ug, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Microbiological degradation of diazepam.
1975
Modification of drug action by hyperammonemia.
1984 Apr
Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury.
1984 Oct
Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine.
1985
Carbon-arsenic bond cleavage by a newly isolated gram-negative bacterium, strain ASV2.
1995 Mar
Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves.
1999 Jun 30
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor.
2000 Jul
Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate.
2001 Apr 6
Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression.
2001 Feb
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during.
2001 Feb
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy.
2001 Feb
In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data.
2001 Feb
Structure of manganese diacetate tetrahydrate and low-temperature methyl-group dynamics.
2001 Feb
Development of xylose-fermenting yeast Pichia stipitis for ethanol production through adaptation on hardwood hemicellulose acid prehydrolysate.
2001 Feb
Screening for cervical neoplasia in a developing country utilizing cytology, cervicography and the acetic acid test.
2001 Feb
Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause.
2001 Feb
Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of Galpha 11 signaling.
2001 Feb 23
Computational studies on nonenzymatic and enzymatic pyridoxal phosphate catalyzed decarboxylations of 2-aminoisobutyrate.
2001 Feb 6
Long-term stability characterization of a controlled release gastrointestinal therapeutic system coated with a cellulose acetate pseudolatex.
2001 Jan
Effect of ruminal vs postruminal administration of degradable protein on utilization of low-quality forage by beef steers.
2001 Jan
Measurement of myocardial blood flow with PET using 1-11C-acetate.
2001 Jan
Immunobiology of the reproductive tract in a female baboon.
2001 Jan
Analgesic activity of Peperomia pellucida aerial parts in mice.
2001 Jan
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
2001 Jan
Effects of zinc acetate on splenocytes of endotoxemic mice: enhanced immune response, reduced apoptosis, and increased expression of heat shock protein 70.
2001 Jan
Inactivation of infective larvae of Angiostrongylus costaricensis with short time incubations in 1.5% bleach solution, vinegar or saturated cooking salt solution.
2001 Jan 15
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores.
2001 Jan 22
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers.
2001 Jan 5
Succinic acid production with reduced by-product formation in the fermentation of Anaerobiospirillum succiniciproducens using glycerol as a carbon source.
2001 Jan 5
p300 does not require its acetylase activity to stimulate p73 function.
2001 Jan 5
The mechanism of beta-hematin formation in acetate solution. Parallels between hemozoin formation and biomineralization processes.
2001 Jan 9
Metabolic fate of [14C]-ethanol into endothelial cell phospholipids including platelet-activating factor, sphingomyelin and phosphatidylethanol.
2001 Jan-Feb
S-methyl-N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against N-methyl-D-aspartate receptor-mediated neurotoxicity.
2001 Jan-Feb
Salt accumulation resulting from base added for pH control, and not ethanol, limits growth of Thermoanaerobacteriumthermosaccharolyticum HG-8 at elevated feed xylose concentrations in continuous culture.
2001 Jan-Feb
Conversion of sugars to 1,2-propanediol by Thermoanaerobacterium thermosaccharolyticum HG-8.
2001 Jan-Feb
Characterization of bioreaction processes: aerobic Escherichia coli cultures.
2001 Nov 30
Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells.
2004 Jun
[Antioxidant enzymes of the rat liver, brain, heart and erythrocytes in ammonia intoxication].
2005 Mar-Apr
Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain.
2005 Oct
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis.
2010 Jan 22
Effects of ammonia and allopurinol on rat hippocampal NMDA receptors.
2010 Mar
Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex.
2010 Sep
Patents

Sample Use Guides

Cyanokit (hydroxocobalamin for injection): one 5 g vial is a complete starting dose
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Unknown
Name Type Language
ACETICUM ACIDUM
HPUS  
Preferred Name English
Acetic acid
FHFI   II   INCI   MART.   MI   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
ACETIC
Common Name English
ACETICUM ACIDUM [HPUS]
Common Name English
NSC-112209
Code English
NSC-127175
Code English
NSC-111201
Code English
ACIDUM ACETICUM GLACIALE
Common Name English
ACETIC ACID [JAN]
Common Name English
Acetic acid [WHO-DD]
Common Name English
ACETIC ACID [VANDF]
Common Name English
NSC-406306
Code English
ORTHOACETIC ACID
Common Name English
ACETIC ACID [MART.]
Common Name English
ACETIC ACID [II]
Common Name English
NSC-115870
Code English
INS NO.260
Code English
ACETIC ACID [WHO-IP]
Common Name English
ETHANOIC ACID
Systematic Name English
ACIDUM ACETICUM [WHO-IP LATIN]
Common Name English
INS-260
Code English
E-260
Code English
NSC-132953
Code English
ORLEX HC COMPONENT ACETIC ACID, GLACIAL
Common Name English
ACETIC ACID [MI]
Common Name English
VINEGAR ACID
Common Name English
TRIDESILON COMPONENT ACETIC ACID, GLACIAL
Common Name English
VOSOL HC COMPONENT ACETIC ACID, GLACIAL
Common Name English
ACETIC ACID [FHFI]
Common Name English
ACETASOL HC COMPONENT ACETIC ACID, GLACIAL
Common Name English
FEMA NO. 2006
Code English
Classification Tree Code System Code
Food Contact Sustance Notif, (FCN No.) FCN NO. 447
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1025
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1081
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 323
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1247
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 724
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 28
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
WHO-ATC S02AA10
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
JECFA EVALUATION ACETIC ACID
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 879
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
NCI_THESAURUS C254
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
FDA ORPHAN DRUG 706219
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
WHO-ATC G01AD02
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
WHO-VATC QG01AD02
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1144
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
DSLD 396 (Number of products:5)
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1096
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 951
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1236
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
CFR 21 CFR 184.1005
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 908
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 728
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 993
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
CODEX ALIMENTARIUS (GSFA) INS-260
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1035
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 887
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1132
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
WHO-VATC QS02AA10
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1089
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 880
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 561
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 140
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
JECFA EVALUATION INS-260
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1082
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 801
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Food Contact Sustance Notif, (FCN No.) FCN NO. 1094
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
Code System Code Type Description
CHEBI
15366
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
WIKIPEDIA
Acetic acid (medical use)
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NSC
406306
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
WIKIPEDIA
ACETIC ACID
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
RXCUI
168
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID5024394
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-580-7
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
RS_ITEM_NUM
1005706
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
SMS_ID
100000088999
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
DRUG CENTRAL
4211
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACPOEIA
ACETIC ACID
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY Description: Clear, colourless liquids. At a temperature below 15 ?C Glacial acetic acid may occur as a translucent, crystalline mass; odour, characteristic and pungent. Miscibility: Miscible with water, ethanol (~750 g/l) TS, and glycerol R. Category: Acidifying agent. Storage: Acetic acid should be kept in a tightly closed container. Additional information: Glacial acetic acid is flammable and should be handled with care. Congealing point, about 15 ?C.
MESH
D019342
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
EVMPD
SUB11689MIG
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL539
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
JECFA MONOGRAPH
3
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
PUBCHEM
176
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NSC
127175
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
CAS
64-19-7
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NCI_THESAURUS
C61623
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NSC
112209
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
MERCK INDEX
m1324
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY Merck Index
HSDB
39
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NSC
132953
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
CAS
463-83-2
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
ALTERNATIVE
DAILYMED
Q40Q9N063P
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
DRUG BANK
DB03166
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NSC
115870
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
EVMPD
SUB12711MIG
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
FDA UNII
Q40Q9N063P
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY
NSC
111201
Created by admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
PRIMARY